The primary purpose of a feasibility trial is to capture early data on the safety and benefit of the ZetaMet™ (Zeta-BC-003) drug before it proceeds to further clinical trials. In addition to safety, researchers can answer other questions in a feasibility trial such as how it works in the body, and/or the side effects associated with increased concentration, etc.
Female patients with metastatic breast cancer to bone, with or without involvement of other sites and with at least one lytic metastatic lesion located in a vertebral body of the spine.
Yes. In the United States, seven (7) patients have already received the product via the FDA’s “Expanded Access/Compassionate Use” program.
Yes. The first and second Compassionate Use patient’s results have been published in a peer-reviewed medical journal. You may read the publication below.
Click the
button above to view in full screen.
University of British Columbia (UBC), Vancouver, BC.
Dr. Diego Villa, dvilla@bccancer.bc.ca
and/or
Dr. Manraj Heran, manraj.heran@vch.ca
“We know that bone metastases are common among late-stage cancer patients and the pain associated with them is debiliatating. We are working diligently to develop ZetaMet™ (Zeta-BC-003) which, if successful, will bring this novel therapy one step closer to a reality for patients who need it most.”
- Joe C. Loy, CEO
ZetaMet™ (Zeta-BC-003), Zetagen’s most advanced drug candidate, is in development to treat metastatic breast cancer to bone. In May 2024, we initiated a feasibility phase 2a clinical trial of ZetaMet™ (Zeta-BC-003) in patients with diagnosed stage IV breast cancer with metastases to the spine (NCT05280067). More information about this trial can be found further down this page.
For information about Zetagen’s Expanded Access Policy, please click here.
Additional information can be found in the following websites: